7,625.02

+44.95

+0.59%

52,309.63

+539.32

+1.04%

25,615.80

+178.80

+0.70%

2,838.45

+26.61

+0.95%

4.8820

-0.0470

-0.95%

18.91

-0.51

-2.63%

3,977.40

+78.50

+2.01%

77,356.50

-663.50

-0.85%

Crude Oil Dec 26

96.83

-7.29

-7.00%

US Private Equity

10,850.63

-82.20

-0.75%

Toronto - Free Realtime Quote CAD

Cardiol Therapeutics Inc. (CRDL.TO)

1.5000 -0.1200 (-7.41%)

As of 11:31:49 AM EST. Market Open.

Loading Chart for CRDL.TO

Chart Range Bar

Interval:

In partnership with ChartIQ

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial

Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Mobilize your Website

View Site in Mobile | Classic

Share by: